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Abstract: The present study aimed to investigate gene expression changes related to cell cycle
activation in patients with spinal cord injury (SCI) and to further evaluate the difference between
the upper and lower limbs of SCI patients. Fibroblasts were obtained from the upper and lower
limbs of SCI patients and healthy subjects. To investigate gene expression profiling in the fibroblasts
from SCI patients compared to the healthy subjects, RNA-Seq transcriptome analysis was performed.
To validate the parasympathetic effects on cell cycle activation, fibroblasts from upper or lower limbs of
SCI patients were treated with the anticholinergic agents tiotropium or acetylcholine, and quantitative
RT-PCR and Western blot were conducted. Cell proliferation was significantly increased in the
upper limbs of SCI patients compared with the lower limbs of SCI patients and healthy subjects.
The pathway and genes involved in cell cycle were identified by RNA-Seq transcriptome analysis.
Expression of cell-cycle-related genes CCNB1, CCNB2, PLK1, BUB1, and CDC20 were significantly
higher in the upper limbs of SCI patients compared with the lower limbs of SCI patients and healthy
subjects. When the fibroblasts were treated with tiotropium the upper limbs and acetylcholine in
the lower limbs, the expression of cell-cycle-related genes and cell proliferation were significantly
modulated. This study provided the insight that cell proliferation and cell cycle activation were
observed to be significantly increased in the upper limbs of SCI patients via the parasympathetic effect.
Keywords: cell cycle; cell proliferation; spinal cord injury; parasympathetic effect
1. Introduction
Spinal cord injury (SCI) initiates several primary and secondary mechanisms causing neuronal cell
death, autonomic and immune dysfunction, sustained neurological deficits, and a significantly high
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risk of morbidity and mortality [1,2]. Following a primary insult such as compression or contusion of
the spinal cord, secondary injury mechanisms, including apoptosis, loss of myelination, and abnormal
ionic homeostasis, lead to the spread of damage from the initial site of injury [3,4].
The cell cycle is crucial in normal physiological conditions; thus, its dysfunction leads to aberrant
cell proliferation [5]. Cell-cycle-related genes and proteins that are upregulated immediately following
SCI are associated with induced glial scar formation and chronic inflammation [6] and induce activation
of both astroglia and microglia as well as the proliferation of these cells [7–9]. According to those effects,
functional recovery and microglia-induced inflammatory responses were found to be significantly
improved following the administration of a cell-cycle-inhibiting drug in a rat model of SCI [10,11].
It has also been reported that cell cycle inhibitors may be potential treatment measures for aged mouse
models of SCI [12]. Taken together, activation of the cell cycle contributes to the pathophysiology of
SCI [6–9,13], but inhibition of the cell cycle should also be neuroprotective in SCI [10–12].
However, most studies have been conducted using in vivo animal models of SCI, while few
studies have provided confirmation of the identified genes in human tissues. Therefore, to identify
differentially expressed genes (DEGs) involved in patients with SCI, we performed gene expression
profiling of fibroblasts from patients with SCI by RNA-Seq transcriptome analysis.
2. Results
2.1. Characteristics of SCI Patients and Healthy Subjects
To obtain fibroblasts, dermal punch biopsies were taken from three paraplegic patients with SCI
and three healthy subjects. In the healthy subjects, fibroblasts were obtained from the chin, back,
and buttock. In the patients with SCI, fibroblasts were obtained from two different regions: the deltoid
muscle of the nondominant arm and the quadriceps muscle. Clinical information of the patients with
SCI is presented in Table S1. Healthy subjects were all males, aged 32, 63, and 76 years old. Similarly,
the patients with SCI were all males, aged 57, 49, and 59 years old. The mean ages of healthy subjects
and patients with SCI were 57 and 55 years, respectively. Mean disease duration in patients with
SCI was 48.7 months. All of the patients were in chronic stage post-SCI, had fully recovered from
spinal shock status, and upper motor signs were predominantly expressed. The neurological level of
injury of the patients with SCI were T5, T4, and T3 and all patients lacked supraspinal modulation
of sympathetic neurons. Their upper limb muscle (represented by the deltoid muscle) was located
above the neurological level of injury, while their lower limb muscle (represented by the quadriceps
muscle) was located below the neurological level of injury. The American Spinal Injury Association
Impairment Scale [14] for all patients was A (indicating complete SCI). The “completeness” of SCI was
confirmed by neurological examination and somatosensory evoked potential test.
2.2. Evaluation of Cell Proliferation in SCI Patients and Healthy Subjects
To evaluate cell proliferation, fibroblasts were seeded in six-well plates and counted with an ADAM
automatic cell counter on days 2, 4, 6, 8, 10, and 12 (Figure 1a). At passage 4, the cell proliferation
in the upper limbs of SCI patients was significantly increased from day 4 compared with healthy
control and lower limbs of SCI patients, respectively. The cell proliferation in the lower limbs of SCI
patients was also significantly increased compared with healthy control from day 6. The cell number
in the upper and lower limbs of SCI patients was particularly higher than the healthy control at
passage 4 (Figure 1a). Especially, the cell number in the upper limbs of SCI patients was significantly
higher than the other two groups. These results indicate that cell proliferation was significantly
increased in the upper limbs of SCI patients.
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Figure 1. Gene expression profile by transcriptome analysis in spinal cord injury (SCI) patients and
healthy subjects. (a) Line graphs show cell numbers of fibroblasts from SCI patients and healthy
subjects from day 0 to 12 at passage 4. Blue line represents fibroblasts from healthy subjects (indicated
as healthy control, n = 9), red line represents fibroblasts from deltoid muscle (indicated as SCI-Upper,
n = 9), and green line represents fibroblasts from quadriceps muscle (indicated as SCI-Lower, n = 6).
* p < 0.05 and *** p < 0.001 comparison with healthy control, and # p < 0.05, ## p < 0.01, and ### p < 0.001
comparison with the SCI-Lower from one-way analysis of variance followed by Bonferroni post hoc
test. (b) Heat map of differentially expressed genes in the fibroblasts from SCI-Upper (n = 3) compared
to healthy control (n = 3) (left panel) and in the fibroblasts from SCI-Lower (n = 2) compared to healthy
control (right panel). The two-way hierarchical clustering method was used to normalize the value,
and the relative expression level of the samples is indicated by color key and z-score. High expression
levels are represented as red and low levels are represented as green. (c) Bar graphs show the number
of differentially expressed genes with fold change ≥ |2.0| in the fibroblasts from SCI-Upper compared to
healthy control (upper graph) and from SCI-Lower compared to healthy control (lower graph). Red bar
represents upregulated genes and green bar represents downregulated genes. (d) Kyoto Encyclopedia
of Genes and Genomes pathway analyses of the differentially expressed genes in the fibroblasts from
SCI-Upper compared to healthy control. Significant terms (* p < 0.05, ** p < 0.01, and *** p < 0.001) are
highlighted in red. (e) The Venn diagrams show the differentially expressed genes for the cell cycle
pathway between SCI-Upper compared to healthy control (represented as red circle) and SCI-Lower
compared to healthy control (represented as green circle).
2.3. Analysis of the Differentially Expressed Genes in SCI Patients and Healthy Subjects
Next, a transcriptome array was performed to identify DEGs in the upper limbs of SCI patients,
lower limbs of SCI patients, and healthy control at passage 4. A heat map of mRNA expression
representing transcripts in the upper limbs of SCI patients compared to healthy control is shown in
Figure 1b (left panel) and that in the lower limbs of SCI patients compared to healthy control is shown
in Figure 1b (right panel).
In the upper limbs of SCI patients compared to healthy control, 15,572 genes were differentially
expressed. Among those genes, 477 transcripts were 2-fold higher and 336 transcripts were 2-fold
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lower in the upper limbs of SCI patients compared with healthy control (Figure 1c, upper panel). In the
lower limbs of SCI patients compared to healthy control, 15,732 genes were differentially expressed.
Among those genes, 206 transcripts were 2-fold higher and 184 transcripts were 2-fold lower in the
upper limbs of SCI patients compared with healthy control (Figure 1c, lower panel).
Especially, DEGs in the SCI patients compared to healthy control were classified with enriched
Kyoto Encyclopedia of Genes and Genomes pathways using DAVID software (Tables 1 and 2). Among
these pathways, the cell cycle pathway was significantly enriched in both the upper (Figure 1d) and
lower limbs of SCI patients compared with healthy control (p < 0.05). Additionally, nine shared
common DEGs, such as cell division cycle 20 (CDC20), pituitary tumor transforming gene 1 (PTTG1),
polo-like kinase 1 (PLK1), cyclin B2 (CCNB2), cyclin B1 (CCNB1), BUB1 mitotic checkpoint serine/threonine
kinase B (BUB1B), BUB1 mitotic checkpoint serine/threonine kinase (BUB1), monopolar spindle 1 kinase (TTK),
and cyclin D1 (CCND1), were significantly upregulated both in the upper and lower limbs of SCI
patients compared with healthy control (Figure 1e, left panel). The fold change (FC) ratio for those
genes is shown in Table 3.
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Table 1. Enriched Kyoto Encyclopedia of Genes and Genomes pathways in the upper limbs of SCI patients.
Term Count p-Value Genes Fold Enrichment
hsa04110:Cell cycle 30 5.46 × 10−12
E2F1, TGFB3, TTK, PKMYT1, PTTG1, CCNE2, CDC45, MCM7, CDKN2B,
BUB1, CCNA2, CDC6, CDK1, SMAD3, CDC20, MCM2, MCM3, CDC25C,
MCM4, MCM5, WEE1, CDKN1C, CCNB1, CCND1, CCNB2, MAD2L1, PLK1,
PCNA, BUB1B, GADD45B
4.503
hsa04512:ECM-receptor interaction 17 6.22 × 10−6 ITGA11, ITGA10, ITGB3, ITGA4, COL5A3, HMMR, LAMA4, CD36, COL6A6,CD44, COMP, ITGA7, COL1A2, RELN, COL1A1, THBS2, COL11A1 3.797
hsa03030:DNA replication 11 1.12 × 10−5 MCM7, LIG1, PRIM2, PCNA, POLA2, MCM2, MCM3, RNASEH2A, MCM4,FEN1, MCM5 5.733
hsa04115:p53 signaling pathway 12 7.90 × 10−4 CCNE2, CCNB1, CDK1, CCND1, CCNB2, CD82, RRM2, SERPINE1, PMAIP1,GADD45B, IGFBP3, GTSE1 3.311
hsa04350:TGF-beta signaling pathway 13 0.002 BMP4, NOG, LTBP1, CDKN2B, COMP, GDF5, TGFB3, SMAD3, ID4, SMURF2,ID3, THBS2, PITX2 2.804
hsa04114:Oocyte meiosis 14 0.005 CDK1, PKMYT1, AURKA, CDC20, IGF2, PTTG1, CDC25C, CCNE2, CCNB1,CCNB2, MAD2L1, PLK1, BUB1, FBXO5 2.388
hsa05412:Arrhythmogenic right
ventricular cardiomyopathy (ARVC) 11 0.006
SLC8A1, SGCG, ITGA7, ITGA11, SGCD, ITGA10, ITGB3, ITGA4, CDH2,
TCF7L2, SGCA 2.716
hsa04510:Focal adhesion 20 0.010
CAV1, PDGFA, ITGA11, ITGA10, ITGB3, ITGA4, COL5A3, CCND1, LAMA4,
COL6A6, COMP, ITGA7, COL1A2, PDGFRA, RELN, PDGFD, COL1A1, THBS2,
COL11A1, MYLK
1.867
hsa05410:Hypertrophic cardiomyopathy
(HCM) 11 0.014
SLC8A1, ACTC1, SGCG, ITGA7, TGFB3, ITGA11, SGCD, ITGA10, ITGB3,
ITGA4, SGCA 2.428
hsa05414:Dilated cardiomyopathy 11 0.023 SLC8A1, ACTC1, SGCG, ITGA7, TGFB3, ITGA11, SGCD, ITGA10, ITGB3,ITGA4, SGCA 2.244
hsa05200:Pathways in cancer 27 0.024
WNT5A, E2F1, FGFR2, FGF5, FGF7, PTGS2, PDGFA, TGFB3, KIT, TCF7L2,
MMP1, CCNE2, WNT2, FOS, CDKN2B, RARB, HHIP, BMP4, FZD8, EPAS1,
SMAD3, BIRC5, MECOM, STAT1, LAMA4, CCND1, PDGFRA
1.545
hsa05416:Viral myocarditis 9 0.033 ICAM1, CAV1, CCND1, SGCG, MYH11, SGCD, ITGB2, HLA-B, SGCA 2.379
hsa04914:Progesterone-mediated
oocyte maturation 10 0.038
CCNB1, CDK1, MAD2L1, CCNB2, PLK1, BUB1, PKMYT1, IGF2,
CDC25C, CCNA2 2.182
Cell cycle pathway is relevant in the upper limbs of SCI patients and is shown in bold letters. These pathways are statistically significant (p < 0.05).
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Table 2. Enriched Kyoto Encyclopedia of Genes and Genomes pathways in the lower limbs of SCI patients.
Term Count p-Value Genes Fold Enrichment
hsa04512:ECM-receptor interaction 12 0.000 COL4A2, COL4A1, TNXB, TNXA, HMMR, LAMA1, SDC1, COMP, COL6A3,RELN, COL1A1, THBS2, COL11A1 5.341
hsa04510:Focal adhesion 13 0.007 CAV1, COL4A2, COL4A1, TNXB, TNXA, LAMA1, CCND1, COMP, COL6A3,RELN, PDGFD, COL1A1, COL11A1, THBS2 2.418
hsa00480:Glutathione metabolism 6 0.010 GSTM1, GGT5, GSTT2B, RRM2, ANPEP, GPX7 4.487
hsa04110:Cell cycle 9 0.017 CCNB1, CCND1, CCNB2, PLK1, BUB1, BUB1B, TTK, CDC20, PTTG1 2.692
hsa04360:Axon guidance 9 0.021 NRP1, UNC5B, SEMA3F, NTN4, NTNG1, SEMA3A, CXCL12, SLIT2, EPHA3 2.609
hsa03320:PPAR signaling pathway 6 0.035 OLR1, SCD, FABP3, SCD5, PCK2, ANGPTL4 3.251
hsa00260:Glycine, serine and
threonine metabolism 4 0.048 PHGDH, DMGDH, PSAT1, CBS 4.824
hsa00250:Alanine, aspartate and
glutamate metabolism 4 0.048 ASS1, ABAT, ASNS, GAD1 4.824
hsa05020:Prion diseases 4 0.065 EGR1, NCAM1, IL6, IL1B 4.273
hsa04114:Oocyte meiosis 7 0.071 CCNB1, CCNB2, PLK1, BUB1, CDC20, AURKA, PTTG1 2.379
Cell cycle pathway is relevant in the lower limbs of SCI patients and is shown in bold letters. These pathways are statistically significant (p < 0.05).
Table 3. Common differentially expressed genes in the upper and lower limbs of SCI patients.
Common Genes SCI-Upper vs. Healthy Control FC SCI-Lower vs. Healthy Control FC
CDC20 7.532 3.483
PTTG1 6.591 2.591
PLK1 5.195 2.571
CCNB2 4.484 2.740
CCNB1 4.298 2.330
BUB1B 4.093 2.302
BUB1 3.722 2.155
TTK 3.410 2.130
CCND1 2.213 2.213
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2.4. Validation of Differential Gene Expression in SCI Patients and Healthy Subjects
Among nine shared common genes, expression levels of CCNB1, CCNB2, PLK1, BUB1, and CDC20
were validated by qRT-PCR in the upper and lower limbs of SCI patients compared to healthy control
(Figure 2a). The gene expression ratios are presented in Table S2. In the upper limbs of SCI patients
compared with healthy control, CCNB1 (p < 0.01), CCNB2 (p < 0.001), PLK1 (p < 0.001), BUB1 (p < 0.001),
and CDC20 (p < 0.001) were significantly increased. In the lower limbs of SCI patients compared with
healthy control, CCNB1 (p < 0.01), CCNB2 (p < 0.05), PLK1 (p < 0.05), BUB1, and CDC20 (p < 0.05) were
increased. In particular, BUB1 (p < 0.01) was significantly increased in the upper limbs of SCI patients
compared with the lower limbs of SCI patients (Figure 2a).
Next, the protein expression of CCNB1, CCNB2, PLK1, BUB1, and CDC20 were validated by Western
blot in the upper and lower limbs of SCI patients compared to healthy control (Figure 2b). The protein
expression ratios are presented in Table S3. In the upper limbs of SCI patients compared with healthy
control, CCNB1 (p < 0.01), CCNB2 (p < 0.001), PLK1 (p < 0.001), BUB1 (p < 0.01), and CDC20 (p < 0.001)
were significantly increased (Figure 2c). In the lower limbs of SCI patients compared with healthy control,
CCNB1, CCNB2, PLK1, BUB1 (p < 0.05), and CDC20 were increased. In particular, CCNB1 (p < 0.05),
CCNB2 (p < 0.001), PLK1 (p < 0.001), and CDC20 (p < 0.001) were significantly increased in the upper limbs
of SCI patients compared with the lower limbs of SCI patients (Figure 2c). These results demonstrate that
the cell cycle was significantly activated in the upper limbs of SCI patients.
Figure 2. Validation of identified genes by transcriptome analysis in SCI patients and healthy subjects.
(a) The relative expression of target genes for qRT-PCR was calculated using the 2−∆∆Ct method. Blue bar
represents fibroblasts from healthy subjects (indicated as healthy control, n = 12), red bar represents
fibroblasts from deltoid muscle (indicated as SCI-Upper, n = 12), and green bar represents fibroblasts
from quadriceps muscle (indicated as SCI-Lower, n = 8). * p < 0.05, ** p < 0.01, and *** p < 0.001 from
one-way analysis of variance followed by Bonferroni post hoc test. (b) Western blot analysis was
performed using antibodies against CCNB1, CCNB2, PLK1, BUB1, CDC20, and GAPDH. (c) Comparison
of relative protein expression from the SCI-Upper (n = 9) and SCI-Lower (n = 9) versus the healthy
control (n = 6). * p < 0.05, ** p < 0.01, and *** p < 0.001 from one-way analysis of variance followed by
Bonferroni post hoc test.
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2.5. Validation of Differential Gene Expression after Tiotropium and Acetylcholine Treatment
The anticholinergic agents tiotropium and acetylcholine have been reported to regulate the
parasympathetic nervous system [15,16]. Therefore, tiotropium or distilled water were treated in
fibroblasts from SCI-Upper and acetylcholine or distilled water were treated in fibroblasts from
SCI-Lower to validate the correlation between patients with SCI and parasympathetic effect.
In the upper limbs of SCI patients treated with tiotropium (indicated as the SCI-Upper+Tio
group), the expression level of CCNB1 (p < 0.05), CCNB2 (p < 0.01), PLK1 (p < 0.001), BUB1 (p < 0.001),
and CDC20 (p < 0.01) was significantly decreased compared with the upper limbs of SCI patients treated
with distilled water (indicated as the SCI-Upper+Veh group), as revealed by qRT-PCR (Figure 3a).
However, in the lower limbs of SCI patients treated with acetylcholine (indicated as the SCI-Lower+Ach
group), the expression level of CCNB1 (p < 0.05), CCNB2 (p < 0.05), PLK1 (p < 0.05), BUB1 (p < 0.05),
and CDC20 (p < 0.001) was significantly increased compared with the lower limbs of SCI patients
treated with distilled water (indicated as the SCI-Lower+Veh group). The gene expression ratios are
presented in Table S4.
Next, the protein expression of CCNB1, CCNB2, PLK1, BUB1, and CDC20 was confirmed by Western
blot (Figure 3b,c). In the SCI-Upper+Tio group compared with the SCI-Upper+Veh group, the expression
of CCNB1 (p < 0.05), CCNB2 (p < 0.001), PLK1 (p < 0.01), BUB1 (p < 0.01), and CDC20 (p < 0.001) was
significantly decreased. However, in the SCI-Lower+Ach group compared with the SCI-Lower+Veh group,
the expression of CCNB1 (p < 0.05), CCNB2 (p < 0.05), PLK1 (p < 0.05), BUB1 (p < 0.001), and CDC20
(p < 0.001) was significantly increased. The protein expression ratios are presented in Table S5. These results
suggest that cell cycle activation was modulated via the parasympathetic effect in patients with SCI.
Figure 3. The effects of tiotropium and acetylcholine in SCI patients. (a) The relative expression of
target genes for qRT-PCR was calculated using the 2−∆∆Ct method. Red bar represents fibroblasts from
SCI-Upper+treated with vehicle (indicated as SCI-Upper+Veh, n = 7–8), light brown bar represents
fibroblasts from SCI-Upper treated with tiotropium (indicated as SCI-Upper+Tio, n = 6), green bar
represents fibroblasts from SCI-Lower treated with vehicle (indicated as SCI-Lower+Veh, n = 5–6),
and black bar represents fibroblasts from SCI-Lower treated with acetylcholine (SCI-Lower+Ach,
n = 5–6). * p < 0.05, ** p < 0.01, and *** p < 0.001 from independent t-test. (b) Western blot analysis was
performed using antibodies against CCNB1, CCNB2, PLK1, BUB1, CDC20, and GAPDH. (c) Comparison
of relative protein expression from SCI-Upper+Tio versus SCI-Upper+Veh and SCI-Lower+Ach versus
SCI-Lower+Veh. * p < 0.05, ** p < 0.01, and *** p < 0.001 from independent t-test; n = 8 per group.
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2.6. Evaluation of Cell Proliferation after Tiotropium and Acetylcholine Treatment
To validate the correlation between cell proliferation and parasympathetic effect in patients with
SCI, cell proliferation was evaluated in the SCI fibroblast after anticholinergic agent or vehicle treatment
(Figure 4a) and the cell numbers of each group were as follows: SCI-Upper+Veh group (27.53 × 104),
SCI-Upper+Tio group (20.86 × 104), SCI-Lower+Veh group (18.79 × 104), and SCI-Lower +Ach group
(26.33 × 104). The cell number of the SCI-Upper+Tio group was significantly decreased compared with
the SCI-Upper+Veh group (p < 0.05). Conversely, the cell number of fibroblasts from the SCI-Lower+Ach
group was significantly increased compared with the SCI-Lower+Veh group (p < 0.05).
Furthermore, we investigated the ERK and AKT pathways, which have been reported to play
an important role in the regulation of growth and proliferation [17] by Western blot analysis (Figure 4b,c).
The expression of phosphorylated Erk/Total Erk and phosphorylated Akt/Total Akt was significantly
decreased in the SCI-Upper+Tio group compared with the SCI-Upper+Veh group (p < 0.05 and p < 0.05,
respectively). However, the expression of phosphorylated Erk/Total Erk and phosphorylated Akt/Total
Akt was significantly increased in the SCI-Lower+Ach group compared with the SCI-Lower+Veh
group (p < 0.05 and p < 0.05, respectively). The protein expression ratios are presented in Table S6.
These results suggest that cell proliferation was modulated via the parasympathetic effect in patients
with SCI.
Figure 4. The effects of tiotropium and acetylcholine on cell proliferation in in SCI patients. (a) Bar
graphs show cell number after treatment with tiotropium and acetylcholine in the fibroblasts from
patients with SCI. Red bar represents fibroblasts from SCI-Upper treated with vehicle (indicated
as SCI-Upper+Veh), light brown bar represents fibroblasts from SCI-Upper treated with tiotropium
(indicated as SCI-Upper+Tio), green bar represents fibroblasts from SCI-Lower treated with vehicle
(indicated as SCI-Lower+Veh), and black bar represents fibroblasts from SCI-Lower treated with
acetylcholine (SCI-Lower+Ach). * p < 0.05 from independent t-test. (b) Western blot analysis was
performed using antibodies against phosphorylated Erk, Total Erk, phosphorylated Akt, Total Akt,
and GAPDH. (c) Comparison of relative protein expression from SCI-Upper+Tio versus SCI-Upper+Veh
and SCI-Lower+Ach versus SCI-Lower+Veh. * p < 0.05 from independent t-test; n = 8 per group.
3. Discussion
In the present study, increased cell proliferation and cell cycle activation were shown in the upper
limbs of paraplegic patients with SCI, suggesting that the parasympathetic nervous system affected cell
proliferation and the cell cycle above the neurological level of injury rather than below it. The possible
cause of the difference is the influence of the autonomic nervous system. Most spinal cord lesions at or
above the sixth thoracic (T6) spinal cord segment result in autonomic dysreflexia [18,19]. Whereas
sympathetic hyperactivity is triggered by autonomic dysreflexia, resulting in systemic vasoconstriction
below the level of the spinal cord lesion [20], parasympathetic activity is induced above the level of the
lesion [21,22]. In this study, each patient had spinal cord lesions above the T6 level with pure supraspinal
disinhibition. In such cases, the parasympathetic nervous system is relatively dominant in the upper
limbs above the neurological level of injury, while the sympathetic nervous system is relatively dominant
in the lower limbs below the neurological level of injury [23]. Previous studies have shown that the
parasympathetic nervous system affects cell proliferation. Pieper et al. reported that acetylcholine,
the major neurotransmitter of the parasympathetic nervous system, stimulates the proliferation of
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human lung fibroblasts and treatment with antimuscarinic drugs inhibits acetylcholine-induced
proliferation [15]. Oben et al. revealed that acetylcholine stimulates proliferation and collagen gene
expression of myofibroblastic hepatic stellate cells [24]. Kurzen et al. reported that the proliferation of
dermal fibroblasts is affected by acetylcholine activity [25].
In the current study, we postulated that parasympathetic dominance above the neurological level
of injury may influence cell proliferation. To confirm this, further experiments were conducted using
acetylcholine and tiotropium treatments. When fibroblasts from the lower limbs of SCI patients were treated
with acetylcholine, which is the final product released by the parasympathetic nervous system [16], cell
proliferation and the expression of target genes increased in the acetylcholine-treated fibroblasts. On the other
hand, when fibroblasts from upper limbs of SCI patients were treated with tiotropium, which is a competitive
antagonist for acetylcholine [15], cell proliferation and the expression of target genes were reduced in the
tiotropium-treated fibroblasts. These results confirmed the relationship between parasympathetic activity,
cell proliferation, and cell-cycle-related gene expression.
In this study, the upregulated genes, such as CCNB1, CCNB2, PLK1, BUB1, and CDC20, were all
involved in maintaining chromosomal stability. Overexpression of these genes is associated with
tumorigenesis by increasing chromosomal instability. Activation of the cell cycle pathway after SCI
and subsequent cell proliferation is associated with a wide range of damage caused by secondary
mechanisms after SCI and may also be associated with a higher risk of cancer in patients with SCI [26].
Another possible cause for the difference in gene expression in the upper and lower extremities
of patients with SCI is the effect of physical activity. Lee et al. and Chen et al. both reported that
physical activity increases astrocyte proliferation, which is associated with regeneration of capillaries
in rat models of ischemic brain injury [27,28]. Szczodry et al. reported that myofibroblast expression
in the patellar tendon in rats was increased in a treadmill exercise group compared with the control
group [29]. In the current study, all of the patients who participated had complete paraplegia and
were able to voluntarily exercise their upper extremities but were unable to spontaneously contract
their lower extremities. Although voluntary activity of the lower extremities was not possible,
therapeutic application of neuromuscular electrical stimulation may result in exercise effects by
contracting muscles [30].
So far, no studies have been reported on the relationship between physical activity and cell
proliferation after SCI. However, considering the results of previous studies, it is possible that the
differences in the amount of physical activity in the upper and lower extremities of the patients may
have contributed to the differences in gene expression associated with cell proliferation and cell cycle
in the current study.
As for the limitations of this study, our data are restricted to three SCI individuals and three healthy
volunteers on a small scale, and the ages of the healthy subjects in this study were not evenly distributed.
A previous study has shown that age is associated with the regulation of mitotic genes [31]. Therefore,
further studies should be conducted on a large scale and considered under a comparison group
containing similar ages. Moreover, the direct comparison between the upper- and lower-limb-derived
cells of healthy and SCI patients from the same region should be investigated further.
In addition, we hypothesized that SCI causes changes in the autonomic nervous system throughout
the whole body. The patient-derived fibroblasts, which were readily available, were used for our
experiment since the biopsy of neuronal tissues is invasive and technically difficult. It will be further
needed to establish human-induced pluripotent stem cells (hiPSCs), generating neural lineage cells
differentiated from the hiPSCs to clarify the relationship between the autonomic nervous system and
either above or below the neurological level of injury in the patients with SCI. Based on this in vitro
study, we should further apply these experimental strategies to SCI patients as in vivo studies to
evaluate the neuroprotection effects of anticholinergic medicines.
Taken together, cell proliferation was significantly increased in the upper limbs of SCI patients
compared with the lower limbs of SCI patients and healthy subjects. Furthermore, the cell cycle
pathway was also significantly activated resulting from the parasympathetic nervous system being
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predominant in the upper limbs of SCI patients compared with the lower limbs of SCI patients.
Our study may provide the relationship between cell cycle and parasympathetic effect in SCI patients;
thus, these findings will be applied in further cell therapy strategies regarding the inhibition of cell
cycle, antiproliferation properties, and the neuroprotective effect in SCI patients.
4. Materials and Methods
4.1. Subjects
Patients and healthy subjects signed informed consent forms prior to the study. Consent for
the collection of human dermal fibroblast samples was included in the study’s written informed
consent form. The Institutional Review Board of Severance Hospital, Yonsei University Health System
approved the consent procedure as well as the entire study (No. 4-2012-0028).
4.2. Preparation of Fibroblast Cells
We performed 3 mm punch biopsies through the full thickness of the dermis in the upper and
lower limbs of the SCI patients with confirmed SCI by a dermatology specialist. Dermal fibroblasts
were also obtained from healthy subjects in the same way. Biopsy samples were transferred to a culture
dish with growth media, Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and
1% penicillin/streptomycin, and incubated in a humidified 5% CO2 atmosphere at 37 ◦C. Tiotropium,
(SigmaAldrich, St. Louis, MO, USA) and acetylcholine (SigmaAldrich, St. Louis, MO, USA) were
treated in the fibroblasts from SCI-Upper and SCI-Lower, respectively. The concentration and treatment
conditions followed previously established methods [15].
4.3. Analysis of Cell Proliferation
To analyze fibroblast proliferation, 10,000 cells were seeded in six-well plates with growth media.
The number of cells per plate were counted with an ADAM automatic cell counter (NanoEnTek Inc,
Seoul, South Korea) after plating.
4.4. RNA Preparation
Total RNA was isolated from cultured fibroblasts obtained from patients with SCI and healthy
subjects using Trizol (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s
instructions [32]. The quantity and purity of RNA were confirmed using a Nanodrop spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA).
4.5. RNA Sequencing and Transcriptome Data Analysis
TruSeqTM RNA Sample prep kits (Illumina, San Diego, CA, USA) were used to prepare the
RNA-Seq transcriptome libraries from total RNA according to the manufacturer’s protocol [33].
Next, the library was sequenced with an Illumina HiSeq 2000plat form (Macrogen Corporation,
Seoul, Korea). To check quality of RNA sequencing data, SolexaQA software [34] was used to
investigate base quality scores from FASTQ files generated by Illumina sequencing technology.
The reads from the FASTQ files were mapped against the human reference genome using TopHat
version 2.0.6 (http://tophat.cbcb.umd.edu/). Transcripts with a fold change ≥ |2.0| and p-value < 0.05
were considered statistically significant and were included in downstream analysis.
4.6. Differentially Expressed Gene Identification and Pathway Analysis
The lists of DEGs were compiled based on the following comparisons: fibroblasts from the
upper limbs of SCI patients compared with healthy subjects and from the lower limbs of SCI patients
compared with healthy subjects. DEGs were submitted to the Database for Annotation, Visualization,
and Integrated Discovery (DAVID v6.7; http://david.abcc.ncifcrf.gov/) [35] via the Kyoto Encyclopedia
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of Genes and Genomes pathway analysis with a fold change ≥ |2.0| and p-value < 0.05. Among the
numerous pathways identified, genes involved in the cell cycle pathway were validated.
4.7. Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was conducted
to validate the transcriptome analysis. Total RNA was reverse-transcribed into cDNA using
a ReverTra Ace® qPCR RT Master Mix with gDNA Remover (Toyobo, Osaka, Japan) according
to the manufacturer’s instructions. The mRNA expression levels for genes of interest were profiled
using qPCRBIO SyGreen Mix Hi-ROX (PCR BIOSYSTEMS, London, UK) with the StepOnePlus
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Data analysis was performed
using the 2−∆∆Ct method [36]. Primers used for qRT-PCR are described in Table S7.
4.8. Western Blot
Proteins were extracted from cultured fibroblasts obtained from patients with SCI and healthy
subjects and were dissolved in RIPA buffer, boiled for 5 min, and loaded onto 4–12% Bis-Tris gels.
Then, separated proteins were blotted onto polyvinylidene difluoride membranes (Invitrogen) with
20% (v/v) methanol in NuPage Transfer Buffer (Invitrogen) at 15 V for 4 h at 4 ◦C. The membranes
were blocked for 1 h in tris-buffered saline containing 0.01% Tween 20 with 5% skim milk (Difco; BD
Biosciences, Oxford, UK), then washed three times with tris-buffered saline containing 0.01% Tween 20
for 10 min. The blots were incubated overnight at 4 ◦C with the following primary antibodies specific to
the target proteins: PLK1, CCNB2, CDC20 (1:1000; Abcam, Cambridge, England), CCNB1, BUB1, ERK,
phosphorylated ERK, AKT, phosphorylated AKT, and GAPDH (1:1000; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The next day, the blots were washed three times with TBST and incubated for
1 h with horseradish peroxidase-conjugated secondary antibodies (1:4000; Santa Cruz, CA, USA) at
room temperature. The blots were washed three times with TBST, then visualized with an enhanced
chemiluminescence detection system (Amersham Pharmacia Biotech, Little Chalfont, UK).
4.9. Statistical Analysis
All data are expressed as mean ± standard error of the mean. Statistical analyses were performed
using the Statistical Package for Social Sciences version 25.0 (IBM Corp. Released 2015. IBM SPSS
Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). Variables between the groups were
analyzed using one-way analysis of variance followed by the Bonferroni post hoc test. An independent
t-test was used for the comparison between vehicle and treatment groups (tiotropium or acetylcholine)
in SCI fibroblasts. A p-value < 0.05 was considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/23/
5982/s1.
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Abbreviations
SCI Spinal cord injury
DEGs Differentially expressed genes
FC Fold change
CDC20 Cell division cycle 20
PLK1 Polo-like kinase 1
CCNB1 Cyclin B1
CCNB2 Cyclin B2
BUB1 BUB1 mitotic checkpoint serine/threonine kinase
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